Jump to content

Recommended Posts

Posted
43 minutes ago, Anastasis said:

Interesting novel therapeutic, pan-flu antiviral, one dose last 28 weeks, covers N5H1, not dependent on strain selection, very high effectiveness in phase 2. 

https://www.cidara.com/news/cidara-therapeutics-announces-positive-topline-results-from-its-phase-2b-navigate-trial-evaluating-cd388-a-non-vaccine-preventative-of-seasonal-influenza/

 

Obviously we should rush to deploy a novel treatment rather than utilize proven, safe, and effective vaccines! 

Posted
Just now, Dahobbs said:

Obviously we should rush to deploy a novel treatment rather than utilize proven, safe, and effective vaccines! 

What the fuck are you talking about? Just clowning. 

Posted
7 minutes ago, Parliament said:

That’s great.  No sarcasm.  So let’s be allowed to take both.  Let’s not restrict traditional vax access to those of us who want to take them.

Agree. Tomorrow ACIP will likely recommend expanded access to Flublock, a recombinant flu vaccine. 

Posted

Promise of Victory Over H.I.V. Fades as U.S. Withdraws Support
A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much of the funding for that effort is gone.

This was supposed to be a breakthrough year in the 44-year-long struggle against H.I.V.

Decades of research and investment produced new approaches to vaccines that were going into their first significant clinical trials.

The hunt for a cure was homing in on key mechanisms to block the virus, which can lurk dormant and near-untraceable in the body for years.

Most critically, a breakthrough preventive drug, lenacapavir, a twice-yearly injection that offers total protection from H.I.V., was to be rapidly rolled out across eastern and southern Africa. The main target: young women. About 300,000 of them were newly infected with the virus last year — half of all new infections worldwide.

Every one of these plans has been derailed by the Trump administration’s slashing of foreign assistance.

There is more potential than ever before to end the H.I.V. epidemic, scientists and public health experts say. But now, H.I.V. programs across Africa are scrambling to procure drugs that the United States once supplied, replace lost nurses and lab technicians, and restart shuttered programs to prevent new infections.

“We imagined we would be in a different world right now,” said Dr. Leila Mansoor, a senior research scientist at the Centre for the AIDS Program of Research in Durban, South Africa. She had planned to spend 2025 analyzing data from one H.I.V. prevention trial, preparing for another and tracking how lenacapavir was transforming the epidemic — alongside colleagues testing new vaccines and cure strategies.

“And instead we’re moving backwards at warp speed,” she said.

Already, there are fears that H.I.V. infection rates are rising in the hardest-hit countries, but there is no clear way to measure the damage because data collection was mostly reliant on the terminated U.S. funding. Stocks of prevention drugs once supplied by the U.S. are running out across Africa.

Quote

 

In South Africa, which has led much of the H.I.V. work in close partnership with the United States, clinical trials of vaccines that had participants ready for their first shot have been canceled, the immunizations left in the back of lab refrigerators. Scientists leading cure studies have laid off their staffs and turned out the lights in their departments.

The Trump administration says that too much foreign aid is wasted by corrupt governments and bloated programs. The president and his allies have repeatedly said that the United States has shouldered an unfair share of responsibility for global health support and that other countries must do more.  

The United States has historically contributed about three-quarters of the global spending on H.I.V., about $6 billion annually in recent years. This is a legacy of a commitment made by President George W. Bush more than two decades ago. Mr. Bush made ending the AIDS pandemic a U.S. priority, saying this was a wealthy nation’s humanitarian obligation, and that it would also benefit American health and security, to bring the deadly virus in check.

Now, even as the Trump administration has dismantled numerous H.I.V. research and prevention programs, Secretary of State Marco Rubio has insisted  that the United States will preserve its support for treatment programs.

Among the prevention programs cut is U.S. support for an ambitious plan to distribute lenacapavir, which the U.S. Food and Drug Administration approved this week. Rapid rollout of the new injection is seen by many public health experts as the best opportunity the world has yet had to stop the spread of H.I.V. in the United States and abroad.

Historically, it has taken years for H.I.V. treatments and prevention methods to reach Africa, where three-quarters of people with the virus live, even when those drugs and interventions were first tested on Africans.

Lenacapavir was supposed to be the product that showed that the world was finally doing things differently, said Dr. Linda-Gail Bekker, director of the Desmond Tutu H.I.V. Centre at the University of Cape Town, who was a principal investigator in the trial that proved the drug’s extraordinary effectiveness.

The company that makes the drug, Gilead Sciences, applied for regulatory approval in African countries where it was tested at the same time as in the United States. The company also issued a voluntary license to makers of generics, including companies in India and Egypt, so that an affordable product would be available in a few years.

To bridge the gap until that time, Gilead committed to producing enough of the drug to protect two million people over three years, to be sold at “a no-profit price.”

However, about half of those doses from Gilead were supposed to be purchased by the President’s Emergency Fund for AIDS Relief, known as PEPFAR. But the Trump administration has decided that PEPFAR should no longer support H.I.V. prevention for anyone except pregnant and breastfeeding women, and will most likely fund only a sliver of the planned Gilead purchase.

The other half of the doses were meant to be bought by the Global Fund to Fight AIDS, Tuberculosis and Malaria, a multilateral donor agency to which the United States has historically been the largest funder. But the Trump administration is also cutting deeply into its support to the Global Fund.

The third potential buyer for lenacapavir is the countries themselves. But many are already straining health budgets to patch gaping holes created by the reduced PEPFAR support and loss of other U.S. assistance.

“The promise of lenacapavir for prevention was — everybody thought this is the last stage to bring the H.I.V. epidemic down to its knees, and there was such enthusiasm for what we would see,” said Dr. Ntobeko Ntusi, the chief executive of the South African Medical Research Council. “That’s now all up in the air.”

Executives at Gilead Sciences say the company is producing the bridge doses now, and publicly say they are confident that the planned two million people will receive the drug.

“Gilead has not stopped or slowed down in our ambition to make sure we get lenacapavir to as many people as possible,” said Janet Dorling, senior vice president for global patient solutions at Gilead. “The changing landscape means we might have to do that differently. I would not tell you that everything is as we expected. But everyone’s working very hard to find a way to make this happen.”

Privately, however, the company is somewhere between anxious and panicked about who will pay for the product, according to people who have been part of negotiations.

Gilead would not disclose what price it would charge for these initial doses for Africa, but H.I.V. program managers in several countries said they had been told the target price was about $100 per patient per year.

That is roughly double what African countries pay for daily H.I.V. prevention pills, but ultimately cost-effective for public health services because it offers much greater protection, said Hasina Subedar, who oversees the design of H.I.V. prevention programs for South Africa’s health ministry. Women who tested the injection said it worked better for them than pills because they didn’t have to remember to do something every day, and they didn’t have to worry about stigma associated with H.I.V.-related tablets that a parent or partner might see.

There is widespread hope in African countries that the Gates Foundation may step in to cover the lost U.S. government funding for the purchase — Bill Gates has often expressed enthusiasm about the potential of lenacapavir to accelerate the end of AIDS — but the foundation is resistant to buying the product from Gilead, the people familiar with the negotiations said, because its executives are reluctant to make a large payment to a major pharmaceutical company.

“We’ve been working on how quickly we can get the generic version activated,” said Trevor Mundel, president of global health at the Gates Foundation. The foundation will guarantee large-volume purchases to encourage the generics makers to ramp up production, he said, in the hope that the low-cost version of lenacapavir is available by early 2027.

But prevention experts are concerned that generic drug makers will be reluctant to scale up production of lenacapavir if demand hasn’t already been proven — potentially keeping supply limited for years. Mitchell Warren, executive director of the H.I.V. prevention organization AVAC, said a potential buyer like the foundation was best placed to negotiate the price down further in this complicated moment for Gilead. (The foundation is a major backer of the Global Fund and would contribute to a lenacapavir purchase in that way.)

Peter Sands, executive director of the Global Fund, has been lobbying politicians in Washington to support lenacapavir, hoping that some part of the U.S. funding pledge for the rollout might be restored.

“If you want countries to take on the responsibility for their H.I.V. responses, in terms of both leadership and funding, it’s a very different thing to take on a problem that is still growing than a problem where you have made a significant dent in the numbers of new infections,” he said. “And lenacapavir gives us that opportunity to dramatically reduce new infections.”

The Children’s Investment Fund Foundation, a British charity, has pledged $150 million to the Global Fund to support the rollout of lenacapavir, and the fund is urgently seeking new philanthropic and private sector donors, Mr. Sands said, as well as urging recipient countries to rejigger their budgets where possible to help fast-track the introduction of lenacapavir.

The South African government, which now pays for the daily oral prevention drug, was counting on PEPFAR assistance to introduce the twice-yearly injection of lenacapavir as an additional, most likely more popular option. Ms. Subedar said South Africa hoped to use it fast and widely, interrupting viral transmission and swiftly pushing infection rates down.

She had envisioned getting lenacapavir to 800,000 young women in 2026, blitzing college dorms and minibus stops. Now, she said, South Africans are once again stuck, knowing a revolutionary technology exists but unsure if and when they will have access to it.

In Eswatini, the country which once had the world’s highest rate of H.I.V. infection, Sindy Matse, program manager of the Swazi National AIDS Program, said the rates of H.I.V. testing in the country had fallen precipitously since January. And from January to April, nearly 5,000 people who take H.I.V. treatment failed to pick up their medication, most likely because their clinics were closed or their outreach workers were fired, she said.

Ms. Matse worries that infected people aren’t starting on treatment and that pregnant women may give birth to infected babies — but she doesn’t know for sure what’s happening because much of her program’s data was collected and processed by clerks whose salaries were paid by PEPFAR and whom the government has yet to replace.

“We never got time to transition,” Ms. Matse said. “Now we are expecting to see new infections, and drug resistance from people whose treatment is interrupted.”

South Africa has also seen a sharp drop in the number of people taking pills to prevent infection. In Cape Town, Dr. Bekker fears that South Africa’s hospitals will soon start to see a surge of people with tuberculosis — people whose H.I.V. treatment has been interrupted, or who have not been diagnosed. Clinicians will need a crash course in what AIDS-related infections look like, she said; young doctors will not have seen them because South Africa’s H.I.V. program has been so effective over the past 15 years. Soon they will be back.

“The stars were aligning, with these new innovations, to really bring this thing to its knees,” she said. “But this money was critical to get there. And now it’s gone.”

 

 

  • Rage+1 8
Posted
15 minutes ago, Anastasis said:

Agree. Tomorrow ACIP will likely recommend expanded access to Flublock, a recombinant flu vaccine. 

More good news.  And a conventional vax for this year’s flu strain?  And this year’s Covid strain?  And no impediments to either?

You understand our reticence.  

Posted
9 minutes ago, bolverk said:

Promise of Victory Over H.I.V. Fades as U.S. Withdraws Support
A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much of the funding for that effort is gone.

This was supposed to be a breakthrough year in the 44-year-long struggle against H.I.V.

Decades of research and investment produced new approaches to vaccines that were going into their first significant clinical trials.

The hunt for a cure was homing in on key mechanisms to block the virus, which can lurk dormant and near-untraceable in the body for years.

Most critically, a breakthrough preventive drug, lenacapavir, a twice-yearly injection that offers total protection from H.I.V., was to be rapidly rolled out across eastern and southern Africa. The main target: young women. About 300,000 of them were newly infected with the virus last year — half of all new infections worldwide.

Every one of these plans has been derailed by the Trump administration’s slashing of foreign assistance.

There is more potential than ever before to end the H.I.V. epidemic, scientists and public health experts say. But now, H.I.V. programs across Africa are scrambling to procure drugs that the United States once supplied, replace lost nurses and lab technicians, and restart shuttered programs to prevent new infections.

“We imagined we would be in a different world right now,” said Dr. Leila Mansoor, a senior research scientist at the Centre for the AIDS Program of Research in Durban, South Africa. She had planned to spend 2025 analyzing data from one H.I.V. prevention trial, preparing for another and tracking how lenacapavir was transforming the epidemic — alongside colleagues testing new vaccines and cure strategies.

“And instead we’re moving backwards at warp speed,” she said.

Already, there are fears that H.I.V. infection rates are rising in the hardest-hit countries, but there is no clear way to measure the damage because data collection was mostly reliant on the terminated U.S. funding. Stocks of prevention drugs once supplied by the U.S. are running out across Africa.

 

Counterpoint: AIDS afflicts the queers and the blacks.  Thus, any treatment for it is DEI, and we've banned DEI.

Seriously, across the board, we have a new national policy of "anything that - even just statistically - benefits a minority/out group more than good American white people, is DEI and must be banned." It extends to literally every public policy area - see, e.g., public health and the post above.  It's fucking jaw-dropping how awful and evil it is, but there we are.

  • Rage+1 1
Posted
5 minutes ago, Brisketexan said:

Counterpoint: AIDS afflicts the queers and the blacks.  Thus, any treatment for it is DEI, and we've banned DEI.

Seriously, across the board, we have a new national policy of "anything that - even just statistically - benefits a minority/out group more than good American white people, is DEI and must be banned." It extends to literally every public policy area - see, e.g., public health and the post above.  It's fucking jaw-dropping how awful and evil it is, but there we are.

Not only that, but stupid as shit because infectious diseases don't recognize national borders, no matter how high a wall gets built.

9yhl9o.jpg 

  • Hook 'Em 1
Posted
37 minutes ago, Anastasis said:

What the fuck are you talking about? Just clowning. 

I get it. You ignore anything and everything that points to obvious anti-science approach of our current administration. You're a pathetic hypocrite and I'll continue to point that out. 

  • Hook 'Em 4
Posted
6 minutes ago, Dahobbs said:

I get it. You ignore anything and everything that points to obvious anti-science approach of our current administration. You're a pathetic hypocrite and I'll continue to point that out. 

I posted a link about a novel anti-viral to the covid influenza black death thread. You vomit on your shoes immediately and reflexively. People can read the thread for themselves. 

Posted
27 minutes ago, Parliament said:

More good news.  And a conventional vax for this year’s flu strain?  And this year’s Covid strain?  And no impediments to either?

You understand our reticence.  

It's all in the materials that I posted on last page. Flu strain selection took place months ago. Regarding COVID, looks like some CDC pushback on the decision to can the recommendation for pregnant women. Generally the safety and effectiveness data are well laid out. Some interesting data in the backup slides on diminished returns in terms of antibody production based on number of prior combined infections/vaccinations.  

Posted (edited)

First Q/A session streaming now. Basically methodology discussions at this point around how VE estimates are influenced by different aspects of study designs re: the observational data presented. 

eta: Safety section Q/A now, Malone chimes in for first time. First point is around transparency regarding details of the safety analyses that have been conducted. Reasonable request I guess, but pretty much a throw away. Second is a question related to the lot to lot variability and whether any of the safety analyses have assessed any relationship. Another series of questions from him later on expanding the safety surveillance to include immunological implications and assessment of longer-term effects. Malones line of questioning is hard to follow.  The MIT guy's as well. Discussion was all handled very well by the CDC reps and their SMEs.

eta2; COVID section over now. No votes scheduled. 

Edited by Anastasis
Posted
3 hours ago, bolverk said:

Promise of Victory Over H.I.V. Fades as U.S. Withdraws Support
A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much of the funding for that effort is gone.

This was supposed to be a breakthrough year in the 44-year-long struggle against H.I.V.

Decades of research and investment produced new approaches to vaccines that were going into their first significant clinical trials.

The hunt for a cure was homing in on key mechanisms to block the virus, which can lurk dormant and near-untraceable in the body for years.

Most critically, a breakthrough preventive drug, lenacapavir, a twice-yearly injection that offers total protection from H.I.V., was to be rapidly rolled out across eastern and southern Africa. The main target: young women. About 300,000 of them were newly infected with the virus last year — half of all new infections worldwide.

Every one of these plans has been derailed by the Trump administration’s slashing of foreign assistance.

There is more potential than ever before to end the H.I.V. epidemic, scientists and public health experts say. But now, H.I.V. programs across Africa are scrambling to procure drugs that the United States once supplied, replace lost nurses and lab technicians, and restart shuttered programs to prevent new infections.

“We imagined we would be in a different world right now,” said Dr. Leila Mansoor, a senior research scientist at the Centre for the AIDS Program of Research in Durban, South Africa. She had planned to spend 2025 analyzing data from one H.I.V. prevention trial, preparing for another and tracking how lenacapavir was transforming the epidemic — alongside colleagues testing new vaccines and cure strategies.

“And instead we’re moving backwards at warp speed,” she said.

Already, there are fears that H.I.V. infection rates are rising in the hardest-hit countries, but there is no clear way to measure the damage because data collection was mostly reliant on the terminated U.S. funding. Stocks of prevention drugs once supplied by the U.S. are running out across Africa.

 

I’m starting to wonder if dotard and his clown show are actually sent back in time to end the human race from advancing too much and keep the population in check. To bolverk’s point, even though they are ostensibly targeting minorities, diseases don’t give a fuck. Maybe this is all part of a plan. Or a simulation. 

  • Hook 'Em 1
Posted
34 minutes ago, Hank_Hill said:

Should be fine

America spoke and decided conspiracy theories, anti-science, hatred towards brown people, being terrified of 1% of the population just trying to live their life, pure uncut nepotism and immature bullying is the new America way

 

  • Hook 'Em 6
Posted (edited)

@Anastasis still thinks this is balanced science and not political bullshit. He still thinks there is nothing to see here and that this is a balanced panel.

https://arstechnica.com/health/2025/06/all-childhood-vaccines-in-question-after-first-meeting-of-rfk-jr-s-vaccine-panel/

All childhood vaccines in question after first meeting of RFK Jr.’s vaccine panel

Beth Mole – Jun 25, 2025 6:04 PM | 116

A federal vaccine panel entirely hand-selected by health secretary and anti-vaccine activist Robert F. Kennedy Jr. gathered for its first meeting Wednesday—and immediately announced that it would re-evaluate the entire childhood vaccination schedule, as well as the one for adults.

The meeting overall was packed with anti-vaccine talking points and arguments from the new panel members, confirming public health experts' fears that the once-revered panel is now critically corrupted and that Kennedy's controversial picks will only work to fulfill his long-standing anti-vaccine agenda.

Controversial committee

An hour before the meeting began, the American Academy of Pediatrics came out swinging against the new panel, saying that the panel's work is "no longer a credible process." The organization shunned the meeting, refusing to send a liaison to the panel's meeting, which it has done for decades.

"We won't lend our name or our expertise to a system that is being politicized at the expense of children's health," AAP President Susan Kressly said in a video posted on social media.

The panel in question, the Advisory Committee on Immunization Practices (ACIP), has for more than 60 years provided rigorous public scientific review, discussion, and trusted recommendations to the Centers for Disease Control and Prevention on how vaccines should be used in the US after they've earned approval from the Food and Drug Administration. The CDC typically adopts ACIP's recommendations, and once that happens, insurance providers are required to cover the cost of the recommended shots.

The system is highly regarded globally. But, on June 9, Kennedy unilaterally and summarily fired all 17 esteemed ACIP members and, two days later, replaced them with eight new people. Some have clear anti-vaccine views, others have controversial and contrarian public health views, and several have little to no expertise in the fields relevant to vaccines.

Last night, it came to light that one of the eight new appointees—Michael Ross, an obstetrics and gynecology physician—had withdrawn from the committee during a financial holdings review that ACIP members are required to complete before beginning work on the panel.

With the remaining seven new members, ACIP's two-day meeting began this morning, despite calls for it to be scrapped. The new ACIP chair, Martin Kulldorff, introduced himself by proudly relaying that he had refused to get vaccinated against COVID-19 and was fired from Harvard University as well as an ACIP working group in the past.

Childhood vaccines under attack

Kulldorff's first order of business was to announce a new working group to review the safety of vaccine schedules in their entirety, rather than the safety of individual vaccines. Kulldorff was echoing an anti-vaccine talking point that children today get too many vaccines.

"In addition to studying and evaluating individual vaccines, it is important to evaluate the cumulative effect of the recommended vaccine schedule," Kulldorff said. "This includes interaction effects between different vaccines, the total number of vaccines, cumulative amounts of vaccine ingredients, and the relative timing of different vaccines."

Although children get more vaccines now than they did in the past, modern vaccines are more efficient at training the immune system against pathogens, exposing them to fewer elements of germs (antigens) to generate protective immune responses. A handy explanation from Yale's School of Public Health notes that children under age 2 in the 1980s got vaccines against just seven diseases—but those vaccines targeted over 3,000 antigens. Today, children under age 2 get vaccines against 15 diseases—but those vaccines target just 180 antigens, asking much less of the immune system.

Further, the cumulative effect of vaccines is baked into testing. When new childhood vaccines are tested in clinical trials, the children participating in those trials are still able to get every other vaccine recommended for them—withholding proven vaccines from participants would be unethical. So, any vaccine safety and efficacy trial includes children who are getting the entire vaccine schedule in addition to the vaccine being tested, providing information on cumulative effects with every new addition.

Kulldorff also said that the panel will go after specific vaccines, including the hepatitis B vaccine, which is given to newborns. The AAP immediately hit back, calling this "unscientific and dangerous." AAP highlighted that the hepatitis B vaccine is safe and lifesaving. Babies infected with hepatitis B at birth have a 90 percent chance of developing chronic disease, and 25 percent with chronic infections will end up dying from it. Thanks to vaccination, there were only 13 cases of hepatitis B in 2022.

“Very concerned”

During the full-day meeting, the seven new members listened to CDC experts review data on COVID-19 vaccines and RSV vaccines and monoclonal antibodies. In the discussions, ACIP member Retsef Levi—who is an expert in operations management—made a puzzling critique that the CDC's method for evaluating COVID-19 vaccine efficacy analysis didn't account for "alternative" explanations like "the vaccine is actually making you more vulnerable for multiple viruses."

Meanwhile, ACIP member Robert Malone—who has claimed to have invented mRNA vaccines and is proud to be called an "anti-vaxxer"—spread false misinformation that certain lots of COVID-19 vaccines were dangerous. ACIP member Vicky Pebsworth—a nurse who is on the board of an anti-vaccine organization—said she was "very concerned" that the CDC's safety monitoring systems were not capturing all of the adverse events from vaccines and said the committee should have access to "data that we probably wouldn't ordinarily have." A CDC subject matter expert noted that there are published studies showing that the CDC's safety monitoring systems capture a large majority of adverse events.

The committee ran over time and did not vote on anything today. But tomorrow, it will vote on an RSV monoclonal antibody discussed today, as well as on influenza vaccines, which will be discussed on Thursday. The agenda also includes presentations on a measles vaccine that has been the target of anti-vaccine activists.

One presentation on flu shots will come from the former president of Kennedy's anti-vaccine organization, the Children's Health Defense. The slides of that presentation have been posted and will focus on the alleged dangers of a mercury-based preservative thimerosal, which anti-vaccine advocates have long falsely linked to autism. Already, researchers and media reports have noted that the presentation supports some of its claims with a study that does not exist.

Edited by Dahobbs
  • Rage+1 1
Posted
1 hour ago, HenryJames said:

The dumbest fucking people.

Are going to convince a bunch of other dumb fucking people to harm their kids.

Might as well bring back polio, if it was good enough for FDR, it was good enough for our kids.

Posted
1 hour ago, atomheartbevo said:

Are going to convince a bunch of other dumb fucking people to harm their kids.

Might as well bring back polio, if it was good enough for FDR, it was good enough for our kids.

Polio will be back.  Mark it 0, dude.

Posted

Got covid last Friday and am on my last dose of Paxlovid today. This new variant was all kinds of fucked up as the symptoms came in waves.  First was the extreme body aches early Friday morning (this was the biggest bitch of all. I still haven't had a full night's sleep since last Thursday due to all the tossing/ turning and hot showers), then came the fatigue later Friday, then congestion Saturday, which led to coughing a couple hours later, and finally, sore throat (almost strep- like) Saturday night. 2am Sunday morning comes around and I'm convinced death is near. I work up the strength to drive to urgent care because surely this "little cold" floating around the office shouldn't feel like this, right? Even the doc was all "well, we should test for flu and covid to be safe, but we haven't seen either floating around recently." 2 nasal swabs and 15 minutes later, and boom. Positive. 

 

I'm really hoping this flu season that covid shots won't be as stupid costly as they were last year, and even moreso, hope that insurance will cover it. First time since the vaccines came out that I didn't get a shot (I think I was told north of $450 and insurance wouldn't cover any of it) and it comes back to no lube me. 

/ rant

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.



×
×
  • Create New...